Laboratory abnormalities worsening from baseline in >10% (all grades) of patients in the LARTRUVO + doxorubicin arm and occurring at a higher incidence than in the doxorubicin arm (between arm difference of ≥5% for all grades or ≥2% for Grades 3 and 4).
*The incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement: LARTRUVO + doxorubicin arm (range 60 to 63 patients) and doxorubicin arm (range 39 to 62 patients).
†aPTT=activated partial thromboplastin time.
Febrile neutropenia: 13% of LARTRUVO + doxorubicin-treated patients vs 12% of doxorubicin-treated patients.1
Cardiac adverse events2
All patients received dexrazoxane prior to doxorubicin in Cycles 5 to 8.
Median cumulative doxorubicin dose
- LARTRUVO + doxorubicin: 488 mg/m2 (7 cycles; 4.9 months)
- Doxorubicin: 300 mg/m2 (4 cycles; 2.8 months)
*Includes ejection fraction decreased, cardiac failure congestive, hepatojugular reflux, jugular vein distension, and left ventricular dysfunction.
†Excludes peripheral edema.